Evaluating the effectiveness of Escitalopram and Buspirone combination therapy in treating late life depression accompanied by impairment in thinking, reasoning, remembering,and problem solving. Escitalopram: Used for depressive symptoms Buspirone: Used for anxiety symptoms and to improve cognition

Assessing the efficacy of combined Escitalopram and Buspirone in late life depression accompanied by cognitive impairment:An open label randomised controlled trail - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/02/104023

Enrollment

Registered

2026-02-16

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F332- Major depressive disorder, recurrent severe without psychotic features Health Condition 2: F331- Major depressive disorder, recurrent, moderate Health Condition 3: F321- Major depressive disorder, singleepisode, moderate Health Condition 4: F322- Major depressive disorder, singleepisode, severe without psychotic features

Interventions

Intervention1: Escitalopram + Buspirone: In the Intervention group, Tab. Escitalopram will be started at 5mg and will be built upto 10mg after 1 week and Tab. Buspirone will be started at 7.5mg BD and

Eligibility

Inclusion criteria

Inclusion criteria: 1)Diagnosed with current Depressive episode according to ICD-11 (Single Episode Depressive Disorder / Recurrent Depressive Disorder)

Exclusion criteria

Exclusion criteria: 1)Diagnosed with current depressive episode in Bipolar affective disorder according to ICD-11 2)Presence of psychotic symptoms 3)Any contraindication to the use of Escitalopram or Buspirone 4)Any other co-morbid major psychiatric disorder(Except Tobacco dependence) 5)On current treatment for dementia

Design outcomes

Primary

Measure	Time frame
To compare the efficacy of combined Escitalopram (10 mg) and Buspirone (30 mg) vs Escitalopram (10 mg) monotherapy in improving cognition among elderly patients with Depression accompanied by cognitive impairment. Timepoint: Improvement in cognition and depressive symptoms will be measured at baseline, 4 weeks and 8 weeks	—

Secondary

Measure	Time frame
1)To compare the efficacy of combined Escitalopram (10 mg) and Buspirone (30 mg) vs Escitalopram (10 mg) monotherapy in improving the depressive symptoms among elderly patients with Depression. 2)To compare the side-effect profile and drop-out from treatment in the combined Escitalopram and Buspirone group as compared with Escitalopram monotherapy group.Timepoint: 4 weeks and 8 weeks	—

Countries

India

Contacts

Public ContactKoushik Sinha Deb

Aiims, New Delhi

Koushik.sinha.deb@gmail.com9868945171

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026